Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $9.238 million which beat the analyst consensus estimate of $5.193 million by 77.88 percent. This is a 19.59 percent decrease over sales of $11.489 million the same period last year.